The results of this study are presented in terms of three main topics: the first involved the use of an experimental colitis model to identify the optimal dose of RvD2n to be used in the assays with human biopsies; the second focused on the biological validation of RNA-sequencing (RNA-seq) analysis and the characterization of RvD2 biosynthesis and activity in CD patients; finally, in the last one, we treated intestinal biopsies from CD patients with both active disease and in remission with RvD2, comparing the effects observed with those of the anti-TNFα treatment. The gene discussed is TNF; the disease is Cowden disease.